CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

191 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
AKRASExon 2 MutationPredictiveSupportsResistanceColorectal CancerCetuximabKarapetis et al., 2008
AKRASMutationPredictiveSupportsResistanceLung Non-small Cell CarcinomaSelumetinib,DocetaxelJänne et al., 2017
AKRASMutationPredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabBenson et al., 2017
AKRASG12CPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaSotorasibSkoulidis et al., 2021
DKRASG12VPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
DKRASG13DPredictiveSupportsSensitivity/ResponseColorectal CancerCetuximabDe Roock et al., 2010
DKRASG12DPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaSelumetinib,DactolisibEngelman et al., 2008
BKRASG13DPredictiveSupportsSensitivity/ResponseColorectal CancerCetuximabDe Roock et al., 2010
BKRASG12PrognosticDoes Not SupportBetter OutcomeColorectal CancerOgino et al., 2009
BKRASG12PrognosticSupportsPoor OutcomeMultiple MyelomaChng et al., 2008
BKRASG13PrognosticSupportsPoor OutcomeMultiple MyelomaChng et al., 2008
BKRASQ61PrognosticSupportsPoor OutcomeMultiple MyelomaChng et al., 2008
BKRASG12/G13PredictiveSupportsResistancePancreatic AdenocarcinomaTrametinib,GemcitabineInfante et al., 2014
DKRASMutationPredictiveSupportsSensitivity/ResponseCancerTrametinibJing et al., 2012
DKRASMutationPredictiveSupportsSensitivity/ResponseColorectal CancerB-Raf/VEGFR-2 Inhibitor RAF265,SelumetinibLamba et al., 2014
DKRASMutationPredictiveSupportsSensitivity/ResponseColorectal CancerTrametinib,AfatinibSun et al., 2014
BKRASMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaSelumetinib,DocetaxelJänne et al., 2013
DKRASMutationPredictiveSupportsSensitivity/ResponsePancreatic AdenocarcinomaSCH772984,PI3Kbeta Inhibitor AZD8186Hayes et al., 2016
BKRASMutationPredictiveSupportsResistanceColorectal CancerChemotherapy,BevacizumabPetrelli et al., 2013
BKRASG13DPredictiveSupportsResistanceColorectal CancerCetuximabRowland et al., 2016
BKRASExon 2 MutationPredictiveSupportsResistancePancreatic CancerGemcitabine,ErlotinibKim et al., 2011
BKRASG12RPrognosticSupportsPoor OutcomePancreatic CancerOgura et al., 2013
BKRASG12DPrognosticSupportsPoor OutcomePancreatic CancerBournet et al., 2016
BKRASMutationPrognosticSupportsPoor OutcomeLung AdenocarcinomaJohnson et al., 2013
DKRASG13DPredictiveSupportsResistanceBreast CancerPictilisibO'Brien et al., 2010
BKRASMutationPredictiveSupportsResistanceColorectal CancerCetuximab,ChemotherapyDe Roock et al., 2010
BKRASQ61PredictiveSupportsResistanceColorectal CancerCetuximab,ChemotherapyDe Roock et al., 2010
DKRASG12RPredictiveSupportsResistanceColorectal CancerCetuximabMisale et al., 2012
BKRASMutationPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaTrametinibBlumenschein et al., 2015
BKRASMutationPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaErlotinib,SelumetinibCarter et al., 2016
DKRASMutationPredictiveSupportsSensitivity/ResponseColorectal CancerPalbociclib,BinimetinibLee et al., 2016
BKRASMutationPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaDocetaxel,ErlotinibRulli et al., 2015
BKRASMutationPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaDocetaxelDouillard et al., 2010
DKRASG10_A11insGOncogenicSupportsOncogenicityColorectal CancerTong et al., 2014
DKRASA11_G12insGAOncogenicSupportsOncogenicityColon AdenocarcinomaTong et al., 2014
BKRASG12CPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDivarasibSacher et al., 2023
AKRASG12CPredictiveSupportsSensitivity/ResponseColorectal CancerCetuximab,AdagrasibYaeger et al., 2024
AKRASG12CPredictiveSupportsSensitivity/ResponseColorectal CancerPanitumumab,SotorasibFakih et al., 2023
BKRASG12DiagnosticSupportsPositiveAcute LeukemiaAndrade et al., 2014
BKRASG12/G13PredictiveSupportsResistanceLung Non-small Cell CarcinomaErlotinib,GefitinibPao et al., 2005
BKRASG12/G13PredictiveSupportsResistanceColorectal CancerCetuximab,ChemotherapyDe Roock et al., 2010
DKRASG12/G13PredictiveSupportsResistanceColorectal CancerCetuximabLièvre et al., 2008
DKRASG12/G13PrognosticSupportsPoor OutcomeColorectal CancerLièvre et al., 2008
BKRASG12DiagnosticDoes Not SupportPositiveLung Non-small Cell CarcinomaRiely et al., 2008
BKRASG12DDiagnosticSupportsPositiveLung CancerDogan et al., 2012
BKRASExon 2 MutationPredictiveSupportsResistanceColorectal CancerCetuximabLièvre et al., 2006
BKRASG12APredictiveSupportsResistanceLung AdenocarcinomaGefitinib,ErlotinibMarchetti et al., 2009
BKRASG12PrognosticDoes Not SupportLung Non-small Cell CarcinomaSchiller et al., 2001
BKRASG12PrognosticSupportsPoor OutcomeMultiple MyelomaChng et al., 2008
BKRASG12PrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaMascaux et al., 2005
Page 1 of 4
Next